vs
Side-by-side financial comparison of AVAX ONE TECHNOLOGY LTD. (AVX) and BIOMERICA INC (BMRA). Click either name above to swap in a different company.
BIOMERICA INC is the larger business by last-quarter revenue ($1.2M vs $1.0M, roughly 1.2× AVAX ONE TECHNOLOGY LTD.). BIOMERICA INC runs the higher net margin — -109.1% vs -1633.6%, a 1524.5% gap on every dollar of revenue.
Biomerica Inc. is a global medical technology company that develops, manufactures and markets diagnostic test kits and related medical products. Its portfolio covers gastrointestinal conditions, infectious diseases, food intolerances and point-of-care testing solutions, serving clinical labs, healthcare providers and retail healthcare segments across North America, Europe and Asia.
AVX vs BMRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.2M |
| Net Profit | $-16.6M | $-1.3M |
| Gross Margin | — | 4.2% |
| Operating Margin | -1522.1% | -113.5% |
| Net Margin | -1633.6% | -109.1% |
| Revenue YoY | — | -26.0% |
| Net Profit YoY | -480.2% | -38.9% |
| EPS (diluted) | $32.17 | $-0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $1.2M | ||
| Q3 25 | $525.9K | $1.4M | ||
| Q2 25 | $452.0K | — | ||
| Q1 25 | $344.4K | $1.1M | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | $0 | $1.8M | ||
| Q2 24 | $41.3K | $1.1M | ||
| Q1 24 | — | $1.0M |
| Q4 25 | $-16.6M | $-1.3M | ||
| Q3 25 | $-8.4M | $2.0K | ||
| Q2 25 | $-8.1M | — | ||
| Q1 25 | $-145.5K | $-1.2M | ||
| Q4 24 | — | $-950.0K | ||
| Q3 24 | $-5.8M | $-1.3M | ||
| Q2 24 | $-4.2M | $-1.4M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | 4.2% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | 22.9% | 1.7% | ||
| Q4 24 | — | 26.7% | ||
| Q3 24 | — | 16.0% | ||
| Q2 24 | 18.4% | 2.1% | ||
| Q1 24 | — | -14.7% |
| Q4 25 | -1522.1% | -113.5% | ||
| Q3 25 | -496.6% | -81.0% | ||
| Q2 25 | -328.4% | — | ||
| Q1 25 | -600.0% | -108.1% | ||
| Q4 24 | — | -60.7% | ||
| Q3 24 | — | -75.7% | ||
| Q2 24 | -2827.7% | -136.6% | ||
| Q1 24 | — | -196.7% |
| Q4 25 | -1633.6% | -109.1% | ||
| Q3 25 | -1588.0% | 0.1% | ||
| Q2 25 | -1783.4% | — | ||
| Q1 25 | -42.2% | -103.9% | ||
| Q4 24 | — | -58.1% | ||
| Q3 24 | — | -72.8% | ||
| Q2 24 | -10243.5% | -127.1% | ||
| Q1 24 | — | -188.6% |
| Q4 25 | $32.17 | $-0.45 | ||
| Q3 25 | $-5.55 | $0.00 | ||
| Q2 25 | $-27.60 | — | ||
| Q1 25 | $-1.17 | $-0.48 | ||
| Q4 24 | — | $-0.06 | ||
| Q3 24 | $-57.19 | $-0.63 | ||
| Q2 24 | $-83.03 | $-2.57 | ||
| Q1 24 | — | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $2.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $187.0M | $4.4M |
| Total Assets | $195.0M | $6.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $2.5M | ||
| Q3 25 | $894.7K | $3.1M | ||
| Q2 25 | $185.3K | — | ||
| Q1 25 | $1.4M | $3.1M | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $2.8M | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $5.3M |
| Q4 25 | — | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $187.0M | $4.4M | ||
| Q3 25 | $12.2M | $5.2M | ||
| Q2 25 | $4.1M | — | ||
| Q1 25 | $6.4M | $5.5M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $6.7M | $5.3M | ||
| Q2 24 | $11.3M | $6.6M | ||
| Q1 24 | — | $7.8M |
| Q4 25 | $195.0M | $6.0M | ||
| Q3 25 | $16.5M | $6.9M | ||
| Q2 25 | $15.2M | — | ||
| Q1 25 | $16.8M | $7.4M | ||
| Q4 24 | — | $7.3M | ||
| Q3 24 | $10.8M | $7.9M | ||
| Q2 24 | $15.7M | $9.3M | ||
| Q1 24 | — | $10.3M |
| Q4 25 | — | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-991.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | $-991.0K | ||
| Q3 25 | $-2.4M | $-268.0K | ||
| Q2 25 | $-884.1K | — | ||
| Q1 25 | $-2.2M | $-1.0M | ||
| Q4 24 | — | $-791.0K | ||
| Q3 24 | $-1.2M | $-1.3M | ||
| Q2 24 | $-919.2K | $-1.0M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-1.1M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -95.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | -134.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
